NCT06427642

Efficacy Evaluation of UCB-MNCs in the Treatment of Refractory Neonatal Diseases

Efficacy Evaluation of Umbilical Cord Blood-derived Mononuclear Cells in the Treatment of Refractory Neonatal Diseases

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Shandong Qilu Stem Cells Engineering Co., Ltd. · Industry
• Sex: All
• Age: 1 Day – 28 Days
• Healthy volunteers: Not accepted

Summary

Hypoxic-ischemic encephalopathy (HIE), bronchopulmonary dysplasia (BPD), short bowel syndrome (SBS) are refractory in clinical treatment. Thus, how to better prevent such diseases is currently a key research topic in the international field. The use of cord blood-derived mononuclear cells may promote to save lives and improve patient outcomes.

Conditions

• Hypoxic-Ischemic Encephalopathy
• Bronchopulmonary Dysplasia
• Short Bowel Syndrome

Interventions

Type	Name	Description
BIOLOGICAL	Mononuclear cells	UCB-MNCs are obtained from umbilical cord blood by density gradient centrifugation
DEVICE	Mild hypothermia therapy	Mild hypothermia therapy via hypothermia therapy apparatus
DEVICE	Breathing support technique	Breathing support via ventilator
PROCEDURE	Total parenteral nutrition	Liquid nutrition injected directly into the bloodstream

Timeline

• Start date: 2022-04-01
• Primary completion: 2024-05-30
• Completion: 2025-04-30
• First posted: 2024-05-24
• Last updated: 2024-05-24

Locations

1 site across 1 country: China